Cytek Biosciences (CTKB) Stock Overview
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CTKB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cytek Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.45 |
| 52 Week High | US$7.63 |
| 52 Week Low | US$2.37 |
| Beta | 1.34 |
| 1 Month Change | 7.14% |
| 3 Month Change | -8.24% |
| 1 Year Change | -44.35% |
| 3 Year Change | -71.32% |
| 5 Year Change | n/a |
| Change since IPO | -81.61% |
Recent News & Updates
APAC Markets And Recurring Revenues Will Support Life Sciences
Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31%
May 30
Recent updates
APAC Markets And Recurring Revenues Will Support Life Sciences
Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31%
May 30Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?
May 05Why Cytek Biosciences Should Beat Q1 Earnings Expectations
Apr 28Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt?
Apr 16Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 13Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
Jan 09Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Nov 07Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Shareholder Returns
| CTKB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -8.2% | 0.6% | -0.5% |
| 1Y | -44.4% | -18.5% | 11.7% |
Return vs Industry: CTKB underperformed the US Life Sciences industry which returned -17.7% over the past year.
Return vs Market: CTKB underperformed the US Market which returned 13% over the past year.
Price Volatility
| CTKB volatility | |
|---|---|
| CTKB Average Weekly Movement | 11.5% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CTKB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CTKB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 663 | Wenbin Jiang | cytekbio.com |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
Cytek Biosciences, Inc. Fundamentals Summary
| CTKB fundamental statistics | |
|---|---|
| Market cap | US$436.97m |
| Earnings (TTM) | -US$11.25m |
| Revenue (TTM) | US$197.05m |
Is CTKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTKB income statement (TTM) | |
|---|---|
| Revenue | US$197.05m |
| Cost of Revenue | US$88.80m |
| Gross Profit | US$108.25m |
| Other Expenses | US$119.50m |
| Earnings | -US$11.25m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.089 |
| Gross Margin | 54.94% |
| Net Profit Margin | -5.71% |
| Debt/Equity Ratio | 1.3% |
How did CTKB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 22:09 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytek Biosciences, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Yuko Oku | Morgan Stanley |